This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rao, C. V. Articles by Reddy, B. S. Search for Related Content PubMed PubMed Citation Articles by Rao, C. V. Articles by Reddy, B. S.

Chemoprevention of Colon Carcinogenesis by Dietary Administration of Piroxicam, -Difluoromethylornithine, 16-Fluoro-5-androsten-17-one, and Ellagic Acid Individually and in Combination¹

Division of Nutritional Carcinogenesis, American Health Foundation, Valhalla, New York 10595 [C. V. R., K. T., J. R., E. Z., B. S. R.]; and Division of Cancer Control and Prevention, National Cancer Institute, Bethesda, Maryland 20892 [G. K.]

The chemopreventive action of 40 and 80% maximum tolerated dose (MTD) levels of piroxicam, D,L--difluoromethylornithine (DMFO), 16-fluoro-5-androsten-17-one (DHEA analogue 8354), and ellagic acid (EA) administered in diet individually and in combination before and during initiation and postinitiation phases of azoxymethane-induced neoplasia of the intestine was studied in male F344 rats. The MTD levels of piroxicam, DFMO, DHEA analogue, and EA were determined in male F344 rats and found to be 500, 5,000, 500, and 10,000 ppm, respectively, in modified AIN-76A diet. When these agents were fed in combination, the MTD levels were: piroxicam plus DFMO, 250 and 2500 ppm; piroxicam plus DHEA analogue, 250 and 250 ppm; piroxicam plus EA, 250 and 5000 ppm; piroxicam plus DFMO plus DHEA analogue, 250, 2500, and 250 ppm; and piroxicam plus DFMO plus EA, 250, 2500, and 5000 ppm. From these MTD values, 40 and 80% MTD levels were calculated and tested for their efficacy. At 5 weeks of age, animals were fed the modified AIN-76A (control) diet and experimental diets containing 40 and 80% MTD levels of piroxicam, DFMO, DHEA analogue, and EA individually and in combination. At 7 weeks of age, all animals except the vehicle-treated groups were administrated s.c. injections of azoxymethane (15 mg/kg body weight/week for 2 weeks). Animals intended for vehicle treatment received s.c. injections of an equal volume of normal saline. Fifty-two weeks after azoxymethane and saline treatment all the animals were necropsied, and colon and small intestinal tumor incidence (percentage of animals with tumors) and multiplicity (tumors/animal) were compared among various dietary groups. The results indicate that 40 and 80% MTD levels of dietary piroxicam and DFMO significantly (P < 0.001) inhibited colon and small intestinal tumor incidence and multiplicity. DHEA analogue at 40% MTD level significantly decreased the small intestinal and colon tumor incidences (P < 0.05), whereas 80% MTD of DHEA analogue inhibited only small intestinal tumor incidence. EA at 40 and 80% MTDs had no significant effect on colon tumor incidence (P > 0.05), but 80% MTD of EA showed a significant inhibitory effect on the incidence of small intestinal adenocarcinomas (P < 0.01). In the combination study, 40 and 80% MTD levels of piroxicam plus DFMO significantly (P < 0.001) inhibited colon adenocarcinoma incidence (8.3%) and multiplicity (0.08 ± 0.04) (SE) when compared to colon adenocarcinoma incidence (72.2%) and multiplicity (1.14 ± 0.18) in control diet-fed animals. These results also demonstrate that low levels of piroxicam and DFMO administered together possess an effective chemopreventive action. Administration of DHEA analogue or EA in combination with piroxicam and DFMO had no additional effect on colon and small intestinal tumorigenesis.

¹ Supported by USPHS Contract NOI-CN-85095-01 and Grant CA-17613 from the National Cancer Institute. Animals were maintained under the guidelines set forth in the Guide for Care and Use of Laboratory Animals Resources, National Research Council.

² To whom requests for reprints should be addressed, at Division of Nutritional Carcinogenesis, American Health Foundation, One Dana Road, Valhalla, NY 10595.

Received 2/15/91. Accepted 6/25/91.

This article has been cited by other articles:

				M. B. Sporn and W. K. Hong Clinical Prevention of Recurrence of Colorectal Adenomas by the Combination of Difluoromethylornithine and Sulindac: An Important Milestone Cancer Prevention Research, June 1, 2008; 1(1): 9 - 11. [Full Text] [PDF]

				D. L. McCormick, W. D. Johnson, N. M. Kozub, K.V.N. Rao, R. A. Lubet, V. E. Steele, and M. C. Bosland Chemoprevention of rat prostate carcinogenesis by dietary 16{alpha}-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone Carcinogenesis, February 1, 2007; 28(2): 398 - 403. [Abstract] [Full Text] [PDF]

				M. V. Swamy, J. M.R. Patlolla, V. E. Steele, L. Kopelovich, B. S. Reddy, and C. V. Rao Chemoprevention of Familial Adenomatous Polyposis by Low Doses of Atorvastatin and Celecoxib Given Individually and in Combination to APCMin Mice. Cancer Res., July 15, 2006; 66(14): 7370 - 7377. [Abstract] [Full Text] [PDF]

				G. D. Stoner, C. Sardo, G. Apseloff, D. Mullet, W. Wargo, V. Pound, A. Singh, J. Sanders, R. Aziz, B. Casto, et al. Pharmacokinetics of Anthocyanins and Ellagic Acid in Healthy Volunteers Fed Freeze-Dried Black Raspberries Daily for 7 Days J. Clin. Pharmacol., October 1, 2005; 45(10): 1153 - 1164. [Abstract] [Full Text] [PDF]

				G. D. Stoner, H. Qin, T. Chen, P. S. Carlton, M. E. Rose, R. M. Aziz, and R. Dixit The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis Carcinogenesis, September 1, 2005; 26(9): 1590 - 1595. [Abstract] [Full Text] [PDF]

				H. Guo, R. M. Ray, and L. R. Johnson RhoA stimulates IEC-6 cell proliferation by increasing polyamine-dependent Cdk2 activity Am J Physiol Gastrointest Liver Physiol, October 1, 2003; 285(4): G704 - G713. [Abstract] [Full Text] [PDF]

				D. E. Corpet and F. Pierre Point: From Animal Models to Prevention of Colon Cancer. Systematic Review of Chemoprevention in Min Mice and Choice of the Model System Cancer Epidemiol. Biomarkers Prev., May 1, 2003; 12(5): 391 - 400. [Abstract] [Full Text] [PDF]

				P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]

				M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]

				C. V. Rao, C. Indranie, B. Simi, P. T. Manning, J. R. Connor, and B. S. Reddy Chemopreventive Properties of a Selective Inducible Nitric Oxide Synthase Inhibitor in Colon Carcinogenesis, Administered Alone or in Combination with Celecoxib, a Selective Cyclooxygenase-2 Inhibitor Cancer Res., January 1, 2002; 62(1): 165 - 170. [Abstract] [Full Text] [PDF]

				A. UMAR, J. L. VINER, and E. T. HAWK The Future of Colon Cancer Prevention Ann. N.Y. Acad. Sci., December 1, 2001; 952(1): 88 - 108. [Abstract] [Full Text] [PDF]

				R. Calaluce, D. L. Earnest, D. Heddens, J. G. Einspahr, D. Roe, C. L. Bogert, J. R. Marshall, and D. S. Alberts Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1287 - 1292. [Abstract] [Full Text]

				A. J. Alberg, G. B. Gordon, S. C. Hoffman, G. W. Comstock, and K. J. Helzlsouer Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate and the Subsequent Risk of Developing Colon Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 517 - 521. [Abstract] [Full Text]

				R. F. Jacoby, C. E. Cole, K. Tutsch, M. A. Newton, G. Kelloff, E. T. Hawk, and R. A. Lubet Chemopreventive Efficacy of Combined Piroxicam and Difluoromethylornithine Treatment of Apc Mutant Min Mouse Adenomas, and Selective Toxicity against Apc Mutant Embryos Cancer Res., April 1, 2000; 60(7): 1864 - 1870. [Abstract] [Full Text]

				B. S. Reddy, T. Kawamori, R. Lubet, V. Steele, G. Kelloff, and C. V. Rao Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis Carcinogenesis, August 1, 1999; 20(8): 1645 - 1648. [Abstract] [Full Text] [PDF]

				H. Li, H. A.J. Schut, P. Conran, P. M. Kramer, R. A. Lubet, V. E. Steele, E. E. Hawk, G. J. Kelloff, and M. A. Pereira Prevention by aspirin and its combination with {alpha}-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon Carcinogenesis, March 1, 1999; 20(3): 425 - 430. [Abstract] [Full Text] [PDF]

				T. Kawamori, R. Lubet, V. E. Steele, G. J. Kelloff, R. B. Kaskey, and C. V. Rao Chemopreventive Effect of Curcumin, a Naturally Occurring Anti-Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer Cancer Res., February 1, 1999; 59(3): 597 - 601. [Abstract] [Full Text] [PDF]